Beiersdorf AG header image

Beiersdorf AG

BEI

Equity

ISIN DE0005200000 / Valor 324660

Xetra (2026-10-02)
EUR 75.40-0.48%

Beiersdorf AG
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

Beiersdorf AG is a global company with a business segment called tesa, which has been operating independently since 2001. tesa is a leading manufacturer of self-adhesive product solutions for industrial customers and consumers, known for its superior technology and high-quality products. The company's business strategy is centered around innovation, constantly working to develop effective solutions for its customers.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (31.08.2026):

Beiersdorf AG — Q2 2026 update: the company has revised its full-year 2026 outlook, citing a volatile market environment and the impact of the Middle East crisis on consumer sentiment, consumption and costs. Management now expects low-single-digit organic sales declines for the Group and the Consumer Business Segment, adjusted EBIT-margin targets, and increased consumer-facing investments to support the NIVEA turnaround; tesa guidance is confirmed but faces semiconductor-related risk. The company forecasts a return to net sales growth in 2027 and profitable above-market growth from 2028.

Guidance update

Beiersdorf now expects Group organic sales to decline low-single-digits in 2026 (previously: flat to slightly growing) and a consolidated EBIT margin excluding special factors of at least 11.8% (previously: slightly below the prior year; prior year Group: 14.0%).

Consumer Business

The Consumer Business Segment is expected to report a low-single-digit organic sales decline in 2026 (previously: flat to slightly growing). EBIT margin (excluding special factors) is now guided to be at least 11.0% (previously: slightly below the prior year; prior year Consumer: 13.6%), reflecting higher investments to support the NIVEA turnaround.

tesa Business

tesa confirms prior guidance of flat to slightly growing organic sales in 2026 and an EBIT margin (excluding special factors) slightly below the previous year’s level. Management flags potential semiconductor shortages that could hurt Electronics sales and tesa’s profitability mix in H2 2026.

Profitability & investments

Beiersdorf will increase consumer-facing investments to accelerate the NIVEA turnaround; this is expected to negatively affect the Consumer EBIT margin in 2026. The revised margins reflect a trade-off between near-term profitability and brand turnaround spending.

Near- and medium-term outlook

Based on current initiatives, the company expects to return to net sales growth in 2027 with EBIT margin stabilization, and from 2028 anticipates returning to profitable growth with net sales growth above market and steady EBIT margin improvement.

Summarized from source with an LLMView Source

Key figures

-16.9%1Y
-38.2%3Y
-19.6%5Y

Performance

32.2%1Y
24.2%3Y
22.6%5Y

Volatility

Market cap

18510 M

Market cap (USD)

Daily traded volume (Shares)

357,085

Daily traded volume (Shares)

1 day high/low

123.5 / 122.65

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Haemonetics Corp
Haemonetics Corp Haemonetics Corp Valor: 937449
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.30%USD 104.68
Sanofi SA
Sanofi SA Sanofi SA Valor: 699381
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-3.13%EUR 70.81
EssilorLuxottica SA
EssilorLuxottica SA EssilorLuxottica SA Valor: 497537
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.24%EUR 142.80
Eurofins Scientific SE
Eurofins Scientific SE Eurofins Scientific SE Valor: 58317129
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.43%EUR 74.86
Legend Biotech Corporation
Legend Biotech Corporation Legend Biotech Corporation Valor: 54834759
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-3.88%USD 18.57
Ionis Pharmaceuticals Inc
Ionis Pharmaceuticals Inc Ionis Pharmaceuticals Inc Valor: 30877188
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.05%USD 43.54
Option Care Health Inc
Option Care Health Inc Option Care Health Inc Valor: 52359365
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.27%USD 22.64
HealthEquity Inc
HealthEquity Inc HealthEquity Inc Valor: 24679014
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.75%USD 90.04
Ensign Group Inc
Ensign Group Inc Ensign Group Inc Valor: 3109721
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.27%USD 171.78
Sotera Health Company
Sotera Health Company Sotera Health Company Valor: 57897071
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.55%USD 18.22